Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 6Withdrawn 2Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Flucytosine × Clear all
NCT04195373 2020-11-25

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Themis Bioscience GmbH

Phase 1 Withdrawn
Gastrointestinal

Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04089163 2020-03-30

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Tocagen Inc.

Phase 1 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡